Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transcytosis of IgG01:15

Transcytosis of IgG

2.7K
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
2.7K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

273
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
273
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

119
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
119
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

1.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IgA nephropathy 'Treatment to Prevention'.

Nephrology (Carlton, Vic.)·2024
Same journal

Effects of Antiresorptive Treatment on Bone Mineral Density and Bone Turnover Markers in a Child With Steroid-Resistant Nephrotic Syndrome: A Case Report.

Nephrology (Carlton, Vic.)·2026
Same journal

Paroxysmal Cold Haemoglobinuria: A Chilling Case of Acute Renal Failure.

Nephrology (Carlton, Vic.)·2026
Same journal

Optimising Therapeutic Target Attainment in Vancomycin Therapy for Patients Requiring Intermittent Haemodialysis.

Nephrology (Carlton, Vic.)·2026
Same journal

Injury to E- and VE-Cadherin in Paediatric Idiopathic Steroid-Sensitive Nephrotic Syndrome: Potential Markers of the Disease Status.

Nephrology (Carlton, Vic.)·2026
Same journal

Finerenone in Treating a 12-Year-Old Boy Suffering Gitelman Syndrome Without Causing Gynecomastia.

Nephrology (Carlton, Vic.)·2026
Same journal

NCOA4-Mediated Ferroptosis Drives Tubulointerstitial Fibrosis in Hyperuricemia-Associated Chronic Kidney Disease.

Nephrology (Carlton, Vic.)·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2025

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.7K

B cell targeting in IgA nephropathy.

Yusuke Suzuki1

  • 1Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.

Nephrology (Carlton, Vic.)
|September 27, 2024
PubMed
Summary
This summary is machine-generated.

IgA nephropathy (IgAN) stems from galactose-deficient IgA1 (GdIgA1) and involves complement activation. New therapies target GdIgA1-producing B cells and pathways, offering hope for IgAN treatment.

Keywords:
B cellIgA nephropathyglomerulonephritis (GN)

More Related Videos

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

1.8K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

6.8K

Related Experiment Videos

Last Updated: Jun 12, 2025

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.7K
Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

1.8K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

6.8K

Area of Science:

  • Nephrology
  • Immunology
  • Pathophysiology

Background:

  • IgA nephropathy (IgAN) is linked to the "multi-hit theory," originating with galactose-deficient IgA1 (GdIgA1).
  • Chronic complement pathway activation (alternative and lectin) drives glomerular damage, leading to proteinuria and fibrosis.
  • GdIgA1 production mechanisms and targeted therapies are under active investigation.

Purpose of the Study:

  • To review the role of responsible B cells in GdIgA1 production.
  • To elucidate the molecular mechanisms underlying GdIgA1 synthesis.
  • To provide an overview of ongoing therapeutic strategies targeting GdIgA1 production.

Main Methods:

  • Review of clinical and basic research findings on IgAN pathogenesis.
  • Analysis of molecular mechanisms involving Toll-like receptors (TLRs), APRIL, and BAFF.
  • Summary of ongoing international clinical trials for novel IgAN therapies.

Main Results:

  • Nephritogenic GdIgA1 is likely polymeric IgA1 of mucosal origin, produced by differentiated B cells.
  • Mucosal innate immunity, including TLRs (TLT9, TLR7), and cytokines APRIL/BAFF, are implicated in GdIgA1 production.
  • Clinical trials are evaluating TLR regulators, anti-APRIL/BAFF agents, and cytoreductive drugs.

Conclusions:

  • Understanding GdIgA1 production by B cells is crucial for IgAN treatment.
  • Targeting GdIgA1 production represents a promising therapeutic avenue for IgAN.
  • Ongoing research and clinical trials are advancing IgAN management.